Trial Profile

A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Oleclumab (Primary) ; Paclitaxel (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms SYNERGY; SYNERGY trial

19 Dec 2024 Planned End Date changed from 1 Apr 2025 to 1 Mar 2025.
19 Dec 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Mar 2025.
23 Sep 2023 Results of Exploratory Biomarker Study from the Synergy Trial presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com